Shire PLC (NASDAQ:SHPG) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 3,854,721 shares, an increase of 38.7% from the November 15th total of 2,779,249 shares. Based on an average daily trading volume, of 1,385,919 shares, the short-interest ratio is presently 2.8 days.
Shire (NASDAQ:SHPG) traded down $0.86 during midday trading on Thursday, reaching $148.41. The company had a trading volume of 1,056,520 shares, compared to its average volume of 1,215,040. The firm has a market capitalization of $44,830.00, a P/E ratio of 27.95, a price-to-earnings-growth ratio of 0.84 and a beta of 1.59. Shire has a 1-year low of $137.17 and a 1-year high of $192.15. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55.
Shire (NASDAQ:SHPG) last posted its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.64 by $0.17. The business had revenue of $3.70 billion during the quarter. Shire had a return on equity of 14.41% and a net margin of 10.95%. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.17 earnings per share. sell-side analysts anticipate that Shire will post 15 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the business. YorkBridge Wealth Partners LLC boosted its position in Shire by 81.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 317 shares during the last quarter. BB&T Investment Services Inc. boosted its position in Shire by 1,672.3% during the third quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 786 shares during the last quarter. Pacer Advisors Inc. bought a new stake in Shire during the second quarter valued at $171,000. Steward Partners Investment Advisory LLC bought a new stake in Shire during the third quarter valued at $159,000. Finally, Stephens Inc. AR boosted its position in Shire by 22.2% during the second quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 228 shares during the last quarter. 20.19% of the stock is currently owned by institutional investors and hedge funds.
SHPG has been the subject of several recent research reports. Zacks Investment Research upgraded Shire from a “sell” rating to a “hold” rating in a research note on Friday, October 27th. Cantor Fitzgerald restated a “buy” rating and set a $222.00 price objective on shares of Shire in a research report on Friday, October 27th. Liberum Capital upgraded shares of Shire from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. Cowen set a $225.00 price objective on shares of Shire and gave the company a “buy” rating in a research report on Friday, January 5th. Finally, ValuEngine upgraded shares of Shire from a “hold” rating to a “buy” rating in a research report on Thursday, October 26th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company. Shire currently has a consensus rating of “Hold” and a consensus target price of $212.18.
WARNING: “Shire PLC (SHPG) Short Interest Up 38.7% in November” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/11/shire-plc-shpg-short-interest-update.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.